New Drug: Retifanlimab in Advanced Merkel Cell Carcinoma

Open-label, multicenter, single-arm, phase 2 study

Treatment naïve metastatic or recurrent locally advanced MCC

Retifanlimab q28 (n=65)

ORR: 52% [40.0%-65.0%]; cR:18%

DOR6 mos: 76% [26 pts of 34]

DOR12 mos: 62% [21 pts of 34]

Any grade AEs: Fatigue, musculoskeletal pain, pruritus, diarrhea, rash, pyrexia, and nausea.

Reviewed by Elvin Chalabiyev, MD on May 20, 2023